CytoMed Therapeutics Ltd. Expands into Auto-Immune Disease Treatments Following Strategic Cord Blood Bank Acquisition
Reuters
Aug 28
CytoMed <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Ltd. Expands into Auto-Immune Disease Treatments Following Strategic Cord Blood Bank Acquisition
CytoMed Therapeutics Ltd., a clinical-stage biopharmaceutical company based in Singapore, has announced its expansion into the field of autoimmune diseases following its acquisition of a cord blood bank. The company has successfully scaled natural killer (NK) cells from cryopreserved cord blood units, setting the stage for establishing a new business platform aimed at generating additional revenue and future growth. Under its restructured group, LongevityBank Pte Ltd will focus on autologous therapies, capitalizing on personalized cellular banking services. Meanwhile, CytoMed will continue to develop donor blood-derived allogeneic therapies, with ongoing clinical trials in Singapore and India. The strategic move positions LongevityBank to potentially spin off as an independent biopharmaceutical entity, concentrating on cord blood-derived treatments for autoimmune conditions. CytoMed anticipates that this expansion will contribute positively to its revenue, leveraging Asia's cost-effective R&D and manufacturing capabilities.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytomed Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9519811-en) on August 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.